ReviewClinical colorectal cancer2011
Prognostic and predictive markers in stage II colon cancer: is there a role for gene expression profiling?
Review in Clinical colorectal cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 85 citations in OpenAlex.
- Lymphovascular invasion is a high risk factor for stage I/II colorectal cancer: a systematic review and meta-analysis.Oncotarget · 2017Pooled it
- The Management and Prognostic Prediction of Adenocarcinoma of Appendix.Scientific reports · 2016Trial
- A comparative analysis and guidance for individualized chemotherapy of stage II and III colorectal cancer patients based on pathological markers.Scientific reports · 2016Trial
- Multi-omics analysis reveals features improving outcomes and immunotherapy resistance in MSS colorectal cancer.iScience · 2026Article
- Article
- Principles of risk assessment in colon cancer: immunity is key.Oncoimmunology · 2024Review
- Identification of ZMYND19 as a novel biomarker of colorectal cancer: RNA-sequencing and machine learning analysis.Journal of cell communication and signaling · 2023Article
- Colorectal cancer concurrent gene signature based on coherent patterns between genomic and transcriptional alterations.BMC cancer · 2022Article
- Machine learning-based integration develops an immune-derived lncRNA signature for improving outcomes in colorectal cancer.Nature communications · 2022Article
- Prognostic and Predictive Molecular Biomarkers for Colorectal Cancer: Updates and Challenges.Cancers · 2020Review
- A network-based predictive gene expression signature for recurrence risks in stage II colorectal cancer.Cancer medicine · 2020Article
- Article
- Assessment of Nuclear ZEB2 as a Biomarker for Colorectal Cancer Outcome and TNM Risk Stratification.JAMA network open · 2018Observational
- Transcriptional subtyping and CD8 immunohistochemistry identifies poor prognosis stage II/III colorectal cancer patients who benefit from adjuvant chemotherapy.JCO precision oncology · 2018Article
- Evolving notions on immune response in colorectal cancer and their implications for biomarker development.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2018Review
- A network-based predictive gene-expression signature for adjuvant chemotherapy benefit in stage II colorectal cancer.BMC cancer · 2017Article
- Article
- A rank-based transcriptional signature for predicting relapse risk of stage II colorectal cancer identified with proper data sources.Oncotarget · 2016Article
- Single Nucleotide Polymorphisms as Prognostic and Predictive Factors of Adjuvant Chemotherapy in Colorectal Cancer of Stages I and II.Gastroenterology research and practice · 2016Review
- Induction of KIAA1199/CEMIP is associated with colon cancer phenotype and poor patient survival.Oncotarget · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Conventional clinical and pathologic risk factors in stage II colon cancer provide limited prognostic information and do not predict response to adjuvant 5-fluorouracil-based chemotherapy. New prognostic and predictive biomarkers are needed to identify patients with highest recurrence risk who will receive the greatest absolute risk reduction from adjuvant chemotherapy. We review below the evidence for conventional risk factors in patients with node-negative colon cancer, followed by a discussion of promising new molecular and genetic markers in this malignancy. Gene expression profiling is an emerging tool with both prognostic and predictive potential in oncology. For patients with stage II colon cancer, the Oncotype DX Colon Cancer test is now commercially available as a prognostic marker, and the ColoPrint assay is expected to be released later this year. Current evidence for both of these assays is described below, concluding with a discussion of potential future directions for gene expression profiling in colon cancer risk stratification and treatment decision making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.